Immunosuppressive and biologic therapy for ulcerative colitis

Author： Ardizzone Sandro Cassinotti Andrea de Franchis Roberto

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.17, Iss.4, 2012-12, pp. : 449-467

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biologic therapies in ulcerative colitis: primi inter pares?

Current Drug Targets, Vol. 19, Iss. 7, 2018-04 ,pp. : 748-756

Bentham Science Publishers

Access to resources Recommend Favorite

Current therapy of ulcerative colitis in children

By Bremner Alan Ronald Griffiths David Mervyn Beattie Robert Mark

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 1, 2004-01 ,pp. : 37-53

Informa Healthcare

Access to resources Recommend Favorite

Rosiglitazone: novel therapy for ulcerative colitis?

Inpharma, Vol. 1, Iss. 1322, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Long-term antibacterial therapy: a role in ulcerative colitis?

Inpharma, Vol. 1, Iss. 1304, 2001-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Beclomethasone is an effective adjuvant therapy to mesalazine in the treatment of active ulcerative colitis

Inpharma, Vol. 1, Iss. 1350, 2002-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite